Psychedelic therapy and psychotherapy - differences and similarities and potential problems for therapists. Prof. Matthew Johnson (Johns Hopkins University) shared his work at the INSIGHT 2021 Conference.
Psychedelics could represent a new treatment approach in psychiatry. But can they combat the global health crisis? At the INSIGHT 2021 Conference, Prof. Dr. Gerhard Gründer takes a critical look on the issue.
For neuroscientist Dr. Martha Havenith, psychedelics are not the only way to explore altered states of consciousness. She works with voluntary hyperventilation (Breathwork) to achieve different perceptions.
Assigning all survivors of an out-of-hospital cardiac arrest (OHCA) to an early coronary angiogram turned out to have no positive influence on the 30-day all-cause mortality.
Thromboprophylaxis with a heparin therapeutic dose greatly reduced major thromboembolic events in COVID-19 hospitalisations compared with standard therapy.
In parts of public discourse and scientific literature, psychedelic therapies are claimed to transform and revolutionise psychiatry and mental healthcare. Can psychedelics live up to this claim?
The MICHELLE trial found rivaroxaban thrombo-prophylaxis beneficial for COVID-19 patients. Some individuals had a 67% risk reduction in clinical outcome composites.
Amidst anti-vaccine passport demonstrators, a masked Dr. Haegy stands alone, with a handmade sign reminding us of some figures: 2,000 intensive care patients, of which 85% were not vaccinated.
Months after infection with SARS-CoV-2, some people are still battling fatigue. In a study, severe fatigue was negatively correlated with disease severity up to 10 months after initial infection.
Intensive livestock has been associated with health risks. Residential exposure to its emitted endotoxin was linked to increased species richness in COPD.
A meta-analysis of three large primary prevention trials showed fixed-dose combination treatments help prevent CV death, MI, stroke, or revascularisation.
The FIGARO-DKD trial investigated mineralocorticoid receptor antagonist treatment effects on cardiovascular outcomes in patients with mild-to-moderate kidney disease and T2D.
IMT consists of breathing exercises. It is a home-based rehabilitation tool that contributes significantly to COVID-19 recovery with only 3 sessions per week.
The DECIDE-Salt trial assessed dietary sodium-reduction strategies over 2 years in residential care patients, targeting significant reductions in systolic blood pressure.
The study showed that diabetic patients with symptomatic PAD and recent peripheral artery revascularisation share benefits from low-dose rivaroxaban with non-diabetics.
Starting with a quadruple combination of hypertensive agents in tiny doses showed to be more effective than standard monotherapy in blood pressure (BP) control.
A novel analysis of DAPA-HF investigated the efficacy of dapagliflozin on ventricular arrhythmia, resuscitated cardiac arrest, and sudden death showing a very reduced likelihood for composite outcome by 21%.
Breathing problems may more frequently precede cardiac arrest than chest pain. Further research can help emergency dispatchers distinguish between symptoms.
The NATURE-PCSK9 study revealed that a yearly vaccine-like approach with PCSK9 small-interfering RNA can reduce cardiovascular events up to two thirds. ‘The earlier the better’ applies in LDL reduction.
The GUIDE-HF trial showed benefits of haemodynamic-guided HF management with an implantable device in reducing HF hospitalisations.